The Pennant Group, Inc. (PNTG) is a Healthcare stock trading at $38.26 (as of 2026-08-25), with a market capitalization of $1.33B and a trailing P/E of 45.1. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
The Pennant Group, Inc. provides healthcare services in the United States through two segments: Home Health and Hospice Services, which include home-based clinical care and hospice services for terminally ill patients and their families, and Senior Living Services, which offer residential living and assistance for seniors. Its services include nursing, therapy, medical social work, home health aide support, and support with activities of daily living.
Understand The Pennant Group, Inc.: how it makes money
The Pennant Group delivers at-home clinical care (nursing, therapy, hospice) and senior-living residences to Medicare, Medicaid, and private-pay patients across multiple U.S. states. Home health and hospice generate about three-quarters of revenue on a per-visit billing basis, while a smaller senior-living portfolio provides recurring room-and-board income.
Profit is a function of patient flow: each home-health episode and each hospice day generates a fixed reimbursable unit, so admissions and census are the primary revenue levers, and labor-intensive care keeps margins thin.
Revenue by segment (latest quarter)
Home Health & Hospice
$0.2B
Senior Living
$0.1B
Other
$0.0B
Business quality (Mixed): Mixed. Revenue is scaling quickly (+36% YoY, largely acquisition-driven), but a 6% operating margin and an 8% ROE show the core care model is labor-heavy with little pricing power against Medicare/Medicaid fee schedules. The senior-living sleeve adds scale but grows more slowly and carries renovation capex.
Valuation: At 45× earnings, PNTG trades 78% above the Healthcare Services average (25×).
Bull case
Mature Sites Are Winning Patients: Management reported that mature operations are gaining market share while same-store margins improve, meaning Pennant is pulling patients away from competitors in established markets and extracting more efficiency per visit. That combination supports both the top line and a path to operating-margin expansion well above the current 6%.
Demographic Tailwind Is Structural: Management noted that aging demographics underpin long-term demand for home health and hospice. Because the per-visit billing model scales with patient flow rather than office expansion, a growing 65+ population creates a recurring demand base independent of new-market entry.
Hartford Opens Northeast Pipeline: The Hartford acquisition gives Pennant a sizable Northeast platform where demographic growth is concentrated. This extends the same per-visit billing playbook into densely populated ZIP codes, adding optionality without building a new clinical network from scratch.
Bear case
California Hospice Cap Limits Revenue: Management acknowledged that hospice cap exposure remains concentrated in California. Because the state cap sets a hard ceiling on reimbursable hospice days, any tightening or population shift would directly compress that revenue line with no pricing lever available to offset it.
Regulatory Scrutiny Raises Admin Costs: Management flagged that ongoing hospice regulatory scrutiny is generating additional administrative overhead. For a business operating at a 6% operating margin, each incremental compliance dollar lands disproportionately on the bottom line and can delay the margin convergence investors are underwriting.
Valuation Prices In Perfection: The stock trades at a P/E of 45.1x versus a 25.4x Healthcare Services industry average, a 78% premium. That multiple embeds sustained high-growth and margin convergence to peers, leaving little cushion if integration disruption in the Southeast or a hospice-policy shift moderates the trajectory.